| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 186.67 | 11.1% |
| Total Income | 186.67 | 11.1% |
| Expenditure | 204.91 | 4.6% |
| PBT | -17.58 | 31.5% |
| Net Profit | -17.11 | 34.0% |
| OPM | -9.77% | 6.79pp |
| NPM | -9.16% | 6.26pp |
| EPS | — |
NeoGenomics Reports Q1 2026 Revenue Up 11% to $187 Million, Raises Full-Year Guidance
29 Apr 2026 · 29 Apr, 2:32 am
Summary
NeoGenomics, Inc. announced strong first quarter 2026 results, with consolidated revenue reaching a record $187 million, an 11% increase year-over-year, driven by a 14% rise in clinical revenue. The company significantly improved its profitability, reducing its net loss by 34% to $17 million and achieving a positive Adjusted EBITDA of $9 million, up 27% from the previous year. Management highlighted the successful launch of the RaDaR® ST MRD assay and favorable coverage for PanTracer™ LBx as key drivers of innovation and market penetration. Reflecting this positive momentum, NeoGenomics increased its full-year 2026 revenue guidance to a range of $797 million to $803 million, signaling confidence in continued growth and market differentiation.
Key Highlights
- 1
NeoGenomics reported a first quarter record consolidated revenue of $187 million, marking an 11% increase year-over-year.
- 2
Clinical revenue demonstrated strong growth of 14%, with Next-Generation Sequencing (NGS) revenue specifically growing by 26% compared to the prior year.
- 3
The company significantly reduced its net loss by 34% to $17 million for the first quarter of 2026.
- 4
Adjusted EBITDA turned positive at $9 million, representing a substantial 27% increase from the first quarter of 2025.
- 5
NeoGenomics raised its full-year 2026 revenue guidance to a range of $797 million to $803 million.
- 6
The company launched RaDaR® ST, a circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD), targeting an estimated $20 billion addressable market.
- 7
NeoGenomics also secured a favorable MolDX coverage decision for its blood-based comprehensive genomic profiling test, PanTracer™ LBx, and introduced PanTracer Pro.
Management Comments
Tony Zook
The first quarter of 2026 was a truly transformational one for NeoGenomics. We again delivered double-digit revenue growth while making meaningful strides in our efforts to bring the latest innovation in advanced cancer testing to the community setting. The full clinical launch of our RaDaR® ST MRD assay in February represents an important advancement in residual disease monitoring, which we estimate represents a $20 billion addressable market that is underpenetrated and growing rapidly. Additionally, we believe the receipt of MolDX reimbursement coverage for PanTracer LBx and the launch of PanTracer Pro addresses a significant need among our customers and complements our PanTracer Tissue offering, which has seen robust growth in test volumes over the past two years. These important additions further differentiate our portfolio, advancing our objective to deliver long-term predictable revenue growth while helping community providers achieve optimal outcomes for their patients.
Informational and educational content only. Not investment advice.